Partial
Mostly Aligned
Patient Risk:
Low
Summary
The claims partially align with the label by acknowledging bleeding risk with omega-3/aspirin combinations and some administration guidance, but numerous dosing, timing, and efficacy-related statements are not supported by the provided labeling and are largely absent from the label.
Category Scores
MonitoringRecommendations
40
Accurate Statements
Aspirin is a known antiplatelet drug that prevents clotting.
Label sections 1 and 7
Combining them may slightly increase bleeding risk (bruising or nosebleeds).
Label sections 5 and 7
Take with food to reduce stomach upset from aspirin.
Label section 2
Track for unusual bruising; adjust under medical guidance.
Label sections 5 and 7
Those with bleeding disorders, ulcers, or recent strokes should consult a doctor.
Label section 5
Unsupported Statements
Most people can take fish oil supplements with aspirin without issues.
Label warns of bleeding risk with concomitant antiplatelet/anticoagulant use; does not support a blanket statement of no issues.
Stop fish oil 7-10 days before procedures.
Not a specific label recommendation in the provided labeling.
People on multiple blood thinners (e.g., warfarin, clopidogrel) face higher risks; monitor INR closely.
Label notes bleeding risk with anticoagulants/antiplatelets but does not require INR monitoring for fish oil combinations.
No issues reported for healthy adults on daily low-dose aspirin for heart protection.
Label does not provide this broad assertion.
Prescription Vascepa (pure EPA) has stronger data with aspirin in trials like REDUCE-IT, showing heart benefits without excess bleeding.
Label does not summarize external trial results for Vascepa-aspirin interactions.
No patents block generics yet.
Patent status not described in the labeling.
High doses (over 4 g) could amplify effects.
Label does not provide a general statement of amplification at doses over 4 g; context-dependent and product-specific.
Stop fish oil 7-10 days before procedures.
Repeated; not a labeled directive in the provided sections.
Studies show no major interactions at typical doses—under 3 g fish oil daily with low-dose aspirin (81 mg).
Label does not quantify 'no major interactions' at specific doses.
Clinical trials, including a 2017 review in Circulation, found no significant rise in bleeding events when omega-3s were added to aspirin or other antiplatelets.
Label does not summarize external trial results.
A large study of heart patients on aspirin plus 4 g fish oil daily saw similar bleeding rates to aspirin alone.
Label does not provide such study-specific bleeding-rate comparisons.
Space doses if concerned—fish oil morning, aspirin evening.
No label guidance on dosing separation.
Standard fish oil (1-2 g EPA/DHA) pairs fine with 81-325 mg aspirin.
No explicit compatibility statements in the label at these doses.
Over-the-counter fish oil works similarly to prescription omega-3s.
Label does not compare OTC vs prescription products.
Prescription Vascepa (pure EPA) has stronger data with aspirin in trials like REDUCE-IT, showing heart benefits without excess bleeding.
Not described in the provided labeling.
Contradictions
Low
AI Statement
Most people can take fish oil supplements with aspirin without issues.
Label Reference
Warnings and Precautions (5); Drug Interactions (7)
Important Omissions
No on-label statements asserting general safety of fish oil with aspirin across doses; no explicit indication details for combined use; no quantified interaction data.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
Label acknowledges bleeding risk with omega-3/aspirin use (5,7); magnitude and context vary by patient factors. The claims include many unsupported statements, but the core label warnings indicate some risk with concomitant therapy.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
Yes |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Many patient-directed claims extend beyond label content (absent from label) and would misrepresent safety/interaction guidance.
Suggested Improvement
Restrict statements to label-supported interactions and warnings; avoid dose-specific interaction claims not present in the label; provide clear on-label guidance for administration (with food) only if supported; remove recommendations about INR monitoring or procedural stops unless explicitly stated in label.